Skip to main content
Top
Published in: Breast Cancer Research 1/2023

Open Access 01-12-2023 | Breast Cancer | Publisher Correction

Publisher Correction: RAGE inhibition blunts insulin-induced oncogenic signals in breast cancer

Authors: M. G. Muoio, M. Pellegrino, V. Rapicavoli, M. Talia, G. Scavo, V. Sergi, V. Vella, S. Pettinato, M. G. Galasso, R. Lappano, D. Scordamaglia, F. Cirillo, A. Pulvirenti, D. C. Rigiracciolo, M. Maggiolini, A. Belfiore, E. M. De Francesco

Published in: Breast Cancer Research | Issue 1/2023

Login to get access

Excerpt

Correction: Breast Cancer Research (2023) 25:84 https://doi.org/10.1186/s13058-023-01686-5
Metadata
Title
Publisher Correction: RAGE inhibition blunts insulin-induced oncogenic signals in breast cancer
Authors
M. G. Muoio
M. Pellegrino
V. Rapicavoli
M. Talia
G. Scavo
V. Sergi
V. Vella
S. Pettinato
M. G. Galasso
R. Lappano
D. Scordamaglia
F. Cirillo
A. Pulvirenti
D. C. Rigiracciolo
M. Maggiolini
A. Belfiore
E. M. De Francesco
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2023
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-023-01689-2

Other articles of this Issue 1/2023

Breast Cancer Research 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine